EFB Dengue Literature Review

Plasmablast

30 min read

Plasmablast

Overview

Plasmablasts are short-lived, rapidly dividing antibody-secreting B cells that arise early in immune responses, typically as the first wave of antibody production before germinal centre reactions mature. They can be generated via extrafollicular pathways (T-dependent or T-independent) and are characterised by high surface CD38 expression, upregulated CD27, loss of surface immunoglobulin, and loss of CD19/CD20 (partially or fully). In dengue, plasmablasts undergo a dramatic and characteristic expansion in peripheral blood during acute infection, peaking approximately days 7–10 post-fever onset.

Key Points from Literature

  • Flow cytometry identification gates: Plasmablasts are identified as: (1) CD38^high, CD19^low, CD20⁻ or (2) CD38^high, IgD⁻, CD20⁻. The CD20⁻ criterion distinguishes plasmablasts from pre-GC cells (Bm2ʹ), which are also CD38^high but remain CD20⁺ and CD19⁺. In the IgD/CD27 scheme, plasmablasts occupy the CD27^high gate (above conventional memory), and CD38^very high expression further separates them from Bm5 memory cells (see Wei2007 - DN Memory B Cells in SLE; Anolik2004 - Rituximab and B Cell Abnormalities in SLE).

  • Dramatic expansion in SLE: Plasmablasts are 18.5 ± 17.9% of CD19⁺ PBL B cells in active SLE patients (range 0–51%, n=15) compared with 0.24 ± 0.23% (range 0–0.5%) in healthy controls (P=0.001). This ~75-fold median expansion illustrates the degree of plasmablast dysregulation in active autoimmune disease (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE).

  • Not directly targeted by rituximab (CD20⁻), yet decline rapidly: Despite being CD20⁻ and therefore not directly susceptible to anti-CD20 depletion, circulating plasmablasts declined in select SLE patients within 2 months of rituximab infusion (patient 11: 40% at baseline → 14% at 2 months, absolute count 3.59 → 0.22 cells/µl). This demonstrates that circulating plasmablasts in this setting are predominantly short-lived and continuously replenished by CD20⁺ B cell precursors. Removal of the precursor pool by rituximab causes rapid plasmablast attrition (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE).

  • Normalization after effective B cell depletion: Across the cohort, plasmablast frequency decreased from 18.5% to 3.9% overall and to 2.4% in effective depletors after immune reconstitution (P=0.009). Patients with ineffective B cell depletion showed less improvement (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE).

  • Short-lived vs. long-lived plasma cell dichotomy: Despite plasmablast normalization in peripheral blood, serum anti-dsDNA autoantibodies persisted in the majority of patients (not significant at 1 year, P=0.3 overall). This dissociation is interpreted as reflecting a two-component plasma cell pool: (1) a short-lived plasmablast population (sensitive to precursor depletion) and (2) a long-lived plasma cell population residing in bone marrow or inflamed tissue niches that is not eliminated by rituximab (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE).

  • DN B cells and conventional CD27⁺ memory cells express CD38 at Bm5/early-Bm5 levels — well below plasmablast levels — confirming they are not misclassified plasmablasts (see Wei2007 - DN Memory B Cells in SLE).

  • CD138⁻ and CD138⁺ maturation stages: Circulating ASCs can be subdivided into CD138⁻ (early plasmablasts) and CD138⁺ (more mature but still-circulating plasmablasts) fractions. Both are Ki67⁺ during SLE flares, confirming they are actively proliferating. Both fractions share clonal lineages (connected by NGS), establishing them as a maturation continuum rather than distinct populations. CD138⁺ ASCs in bone marrow of non-flaring SLE patients are Ki67⁻, distinguishing the long-lived quiescent plasma cell pool from the proliferative circulating fraction (see Tipton2015 - ASC Diversity and Origin in SLE, polychromatic flow cytometry, n=5 SLE flare).

  • All circulating SLE ASCs are Ki67⁺: Ki67 staining confirmed that both CD138⁻ and CD138⁺ circulating ASC fractions in SLE flares are in active cell cycle — all represent proliferative plasmablasts at various differentiation stages. This distinguishes them from the quiescent long-lived plasma cells in bone marrow (see Tipton2015 - ASC Diversity and Origin in SLE).

  • SLE ASC polyclonality: In acute SLE flares, ASCs are strikingly more polyclonal than vaccine-elicited ASCs (D20 ~199 vs. ~21). The majority of circulating plasmablasts during SLE flares are not classically autoreactive — anti-dsDNA + anti-Ro + anti-Sm together account for <3% of IgG⁺ ASCs even in patients with large expansions. Polyclonal bystander activation of memory ASCs (including influenza- and tetanus-specific cells) is a major component (see Tipton2015 - ASC Diversity and Origin in SLE, ELISPOT and NGS).

  • Activated naive (acN) cells as EF plasmablast precursors: Up to 32.5% of acN cell (CD19^hi, MTG⁺, CD24⁻, CD21⁻, CD23⁻) BCR sequences are clonally connected to co-circulating ASCs. acN cells persist for months and continuously seed new ASC progeny, with progeny accumulating up to 21.5% VH SHM from unmutated precursors. This is the most direct human evidence to date for an EF naive→plasmablast differentiation axis (see Tipton2015 - ASC Diversity and Origin in SLE).

  • DN2 cells as direct pre-plasmablasts: DN2 cells are poised PC precursors with high IRF4, BLIMP-1, and open PRDM1 chromatin. DN2 cultures produce IgG at higher per-cell levels than DN1 or SWM, and generate IgG ASC frequencies comparable to SWM by ELISPOT. DN2 → PC differentiation is driven by TLR7 + IL-21 + IFN-γ, requires TLR7 (removing R848 causes >95% death), and proceeds without BCR stimulation or extensive cell division. DN2 cells also produce anti-Sm, anti-RNP, and anti-Ro autoantibodies at titers comparable to SWM cultures (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, in vitro differentiation + LIPS + ELISPOT).

  • Clonal connectivity between aNAV, DN2, and PC: BCR sequencing demonstrates clonal sharing between all three populations — in vivo evidence of the aNAV → DN2 → plasmablast developmental pathway. IgG mutation rate in DN2 is similar to PC but lower than SWM, arguing against derivation from memory cells (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • DN2 expansion correlates with PC expansion: Patients with high DN2 frequencies tend to have high PC frequencies, consistent with DN2 cells being the immediate precursor pool (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • DN3 cells as circulating pre-plasmablasts: DN3 B Cells (IgD⁻CD27⁻CXCR5⁻CD21⁻CD11c⁻T-bet⁻) represent a distinct pre-plasmablast population that accumulates in tissues in autoimmune fibrosis and severe COVID-19. They correspond to early ASC stages before CD27/CD38 upregulation. DN3 should not be conflated with DN2 or ABC despite sharing CD21lo phenotype (see Sanz2025 - Human Atypical B Cells Overview, review).

  • DN2 in RA synovium as main ASC precursor: In rheumatoid arthritis, DN2 cells in the synovium represent the main precursor of ASC — extending the DN2→PB pathway from SLE to other autoimmune diseases (see Sanz2025 - Human Atypical B Cells Overview, review citing Wing et al. 2023).

  • Massive ASC expansion in severe COVID-19: ICU-C patients had significantly higher ASC frequencies than OUT-C or HD (P ≤ 0.05). ASCs constituted up to 27% of CD19⁺ B cells in representative ICU patients (vs. 0.64% in HD). The ASC expansion correlated with the EF pathway cluster (aN + DN2 + DN3) in hierarchical clustering (see Woodruff2020 - EF B Cell Responses in COVID-19, spectral FCM, n=10 ICU-C).

  • CD138⁺ ASC enrichment in severe COVID-19: ICU-C patients had significantly higher CD138⁺ ASC frequencies (both of total CD19⁺ and of total ASCs) relative to OUT-C and HD. In a representative ICU patient, CD138⁺ cells were 53% of ASCs vs. 5.9% in HD — a response feature previously observed in SLE (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • ASC repertoire dominated by germline VH clonotypes: Single-cell V(D)J sequencing of ASCs from a CoV-A patient (day 12 post-symptom onset; 5,338 cells, 2,017 clonotypes) revealed that >50% of clonotypes had exclusively germline (unmutated) VH genes, especially in the IgG1 and IgA1 compartments. This is consistent with newly recruited EF-derived ASCs rather than memory recall (see Woodruff2020 - EF B Cell Responses in COVID-19, 10x Chromium single-cell V(D)J).

  • Balanced IgM/IgG1/IgA1 isotype usage with ongoing CSR: ASC isotype usage showed balanced IgM, IgG1, and IgA1 representation. >3% of clonotypes had cellular members in both unswitched (IgM) and switched compartments, with 60% of the top 15 clonotypes showing contemporaneous IgM↔IgG1/IgA1 connections — direct evidence of ongoing class switch recombination (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • Oligoclonal expansions with antigen selection: Top 10 clonotypes constituted >12% of total repertoire. Complex branching lineage trees with class switching and broad SHM range indicated robust antigen selection. Bulk V(D)J from 2 additional ICU patients showed individual clonotypes contributing 1–8% of total repertoire (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • High neutralizing antibodies produced despite EF origin: CoV-A patients had the highest anti-SARS-CoV-2 RBD serum antibodies (IgM, IgG, IgA) with significantly elevated titers by day 5 post-symptom onset and confirmed in vitro neutralization — yet these patients had the worst clinical outcomes. This establishes that EF-derived, germline-dominant ASC responses can produce functional neutralizing antibodies (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • TISSUE-LEVEL: IgG⁺ plasmablasts at both follicular and extrafollicular sites in COVID-19: Post-mortem immunofluorescence showed IgG⁺ class-switched plasmablasts prominent in both follicular and extra-follicular areas of COVID-19 lymph nodes and spleens. In peripheral blood, plasmablasts expanded in severe CRP-high patients alongside activated naive, DN2, DN3, and switched memory cells — all confirmed SARS-CoV-2 RBD-specific by dual-fluorophore probes. This tissue evidence, combined with the loss of Bcl-6⁺ GC B cells, demonstrates that plasmablast generation in fatal COVID-19 occurs entirely through the extrafollicular pathway (see Kaneko2020 - GC Loss and TFH Block in COVID-19, tissue: n=11 COVID + controls, multi-color immunofluorescence; blood: n=68, 13-color FCM).

  • DENV plasmablasts in 1° vs 2° dengue: In acute dengue, total plasmablasts (CD38+/CD27+ within IgD⁻/CD20⁻) did not differ between 1° and 2° infection. However, IgM⁻ PBs (likely IgG+) were significantly higher in 2° than 1° acute dengue (p<0.05, n=4/group), consistent with memory recall generating class-switched ASCs. IgM+ PBs were quantified separately since IgM BCR is maintained on PB surfaces but IgG BCR expression is variable (see Singh2026 - DENV-Specific Memory B Cell Subsets, n=4/group acute timepoint).

  • Massive plasmablast expansion in acute dengue — full phenotype defined: Plasmablasts in acute dengue are CD20⁻CD38⁺⁺CD27⁺Ki67⁺CD71⁺CXCR3⁺ — massively expanded in both primary and secondary infection. The CXCR3⁺ phenotype is consistent with the CXCR5↓/CXCR3↑ EF homing switch described in COVID-19. Ki67⁺ and CD71⁺ confirm active proliferation and high metabolic demand (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue, multi-color FCM, n=170 acute dengue).

  • Tph-driven plasmablast generation from memory B cells: Peripheral Helper T Cell (CXCR5⁻PD-1⁺) cells drive class-switched memory B cell → plasmablast differentiation via IL-21. Blocking IL-21 reduces plasmablast output by ~60%. Naive B cells are poor responders — contrasting with SLE, where naive (acN) cells are the dominant EF ASC precursors (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue, T-B coculture).

  • Severity-associated antibody output without increased neutralization: Plasmablast-derived antibodies (anti-NS1, anti-prM/M/E IgG) are elevated in severe dengue, but FRNT₅₀ neutralizing titers do not differ between mild and severe groups — replicating the neutralizing Ab paradox from COVID-19 (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue; cf. Woodruff2020 - EF B Cell Responses in COVID-19).

  • FOUNDATIONAL: First systematic dengue plasmablast characterisation — 47% of B cells, >1,000-fold expansion, day 6–7 peak: In a Bangkok hospital cohort (n=46 confirmed dengue, 42 secondary), plasmablasts (CD19⁺CD3⁻CD20⁻/low CD27^high CD38^high) averaged 47% of CD19⁺ B cells, with peak individuals reaching 30% of total lymphocytes. Median absolute count was 3.7 × 10⁵/ml blood — a >1,000-fold increase over healthy donors. The response peaked at day 6–7 post-fever onset (barely detectable at days 2–3) and returned to baseline by 1 month post-discharge. The magnitude significantly exceeded influenza booster (2–3% of B cells, day 7 peak) and yellow fever primary vaccination (day 11–14 peak) — both p<0.0001. Despite massive expansion, total serum IgG was not elevated, indicating most plasmablasts are short-lived (see Wrammert2012 - Plasmablast Responses in Acute Dengue, n=46 cohort, 5-color conventional FCM + BD Trucount).

  • ≥70% of dengue plasmablasts are DENV-specific IgG-secreting cells: ELISpot with DENV-2 (strain 16681) showed the response was dominated by DENV-specific IgG, with ≥70% (often ≥80%) of IgG-secreting cells binding DENV antigen. IgA responses were ~100-fold lower; IgM was near-absent (only detectable in the 4 primary responders). Cross-serotype reactivity was confirmed: no significant difference in DENV-specific frequency between DENV-1, -2, and -3 patients, indicating shared epitope targeting (see Wrammert2012 - Plasmablast Responses in Acute Dengue, ELISpot).

  • No severity correlation in this cohort (but confounded): DF and DHF did not differ in plasmablast magnitude or kinetics. The authors acknowledge this was confounded by all patients being hospitalised — subsequent work (GarciaBates2013) with outpatient and OFI controls resolved this, showing plasmablasts scale with severity (see Wrammert2012 - Plasmablast Responses in Acute Dengue, n=28 DF vs n=18 DHF).

  • LANDMARK: Plasmablast magnitude scales with dengue severity — 46% mean, 87% peak in severe secondary infection: In a Brazilian hospital cohort (n=84), plasmablasts (CD27⁺CD21⁻CD20⁻CD38⁺) averaged 46% of B cells in secondary DFC at days 4–7, significantly exceeding secondary DF, primary DFC, primary DF, and OFI (5%). One individual reached 87% plasmablasts. Peak expansion was restricted to days 4–7 post-symptom onset in both primary and secondary infection, with secondary responses substantially greater (anamnestic recall). Naive B cells contracted to ~30% in secondary DFC (from ~50% in controls), reflecting displacement by the plasmablast wave (see GarciaBates2013 - Plasmablast Response and Dengue Severity, n=84 cohort, conventional FCM).

  • >70% of plasmablasts are DENV-specific in severe secondary dengue: ELISpot demonstrated ~40,000 DENV-3-reactive IgG-secreting cells per 10⁶ PBMC in secondary DFC (n=9), representing 72% of all IgG-secreting cells. The frequency of DENV-specific cells was independent of total plasmablast percentage (individuals with 4% and 87% plasmablasts both had >80% DENV-specificity). Minor influenza virus cross-reactivity (0.7% of IgG ASCs) was also detected (see GarciaBates2013 - Plasmablast Response and Dengue Severity, ELISpot).

  • Serotype cross-reactivity with 3-fold infecting-serotype preference: Plasmablasts from secondary DFC (n=14) reacted with DENV-1, DENV-2, and DENV-3, but with 3-fold higher reactivity to the infecting serotype (DENV-3) than to heterotypic serotypes (p<0.01). This contrasts with the Nicaraguan pediatric cohort (Zompi et al. 2012) which found higher cross-reactivity to the previous infecting serotype — the difference may reflect the longer interval between primary and secondary infection in Brazilian adults (see GarciaBates2013 - Plasmablast Response and Dengue Severity, ELISpot).

  • Plasmablast frequency does not correlate with PRNT₅₀ neutralizing Ab titers: Despite massive plasmablast expansion, PRNT₅₀ titers to DENV-1, -2, -3, and -4 showed no correlation with plasmablast percentage at days 4–7 in either secondary DF or secondary DFC. This is the earliest demonstration of the plasmablast-neutralization disconnect in dengue, now confirmed by Ansari2025 using FRNT₅₀ (see GarciaBates2013 - Plasmablast Response and Dengue Severity, PRNT).

  • B cell activation-induced apoptosis in severe dengue: ~60% of B cells in secondary DFC expressed active caspase-3 (apoptosis marker), positively correlated with Ki-67⁺ proliferation (r=0.44, p=0.0003) and CD95 (Fas) expression (r=0.60, p<0.0001). This suggests activation-induced cell death paralleling the T cell apoptosis pattern in dengue — and is notable given the DN2 apoptosis resistance described in SLE (Scharer2019) (see GarciaBates2013 - Plasmablast Response and Dengue Severity, intracellular FCM).

  • Plasmablasts and convalescent MBCs are clonally distinct in dengue: In a longitudinal study of 12 DENV-2 patients (8 secondary, 4 primary), very few CDR3 sequences were shared between acute-phase plasmablasts (CD19⁺CD20⁻CD27^hiCD38^hi, days 3–7) and convalescent DENV-binding memory B cells (CD19⁺CD20⁺CD27⁺, days 16–166). Even relaxing to 85% CDR3 identity yielded minimal overlap (e.g., 7 of 97 PB clones in Patient 3). The rare shared clones were exclusively IgM — no shared IgG CDR3s were found. This demonstrates that the plasmablast response represents a small, non-representative subset of the broader DENV-specific MBC pool (see Appanna2016 - Plasmablasts as Subset of Memory B Cell Pool, n=12 cohort, Sanger + 454 sequencing).

  • Plasmablast-derived mAbs are 85% E protein-specific; MBC-derived mAbs are not: Of 75 PB-derived mAbs, 85.3% recognised recombinant E protein; 14.7% recognised complex epitopes; none were prM-specific. Of 45 MBC-derived mAbs, only 17.8% were E-specific; 55.6% recognised complex epitopes; 24.4% were prM-specific. E-specific mAbs (PB-derived) neutralised DENV at 0.1–10 µg/ml (NT50), whereas complex epitope-specific mAbs required >10 µg/ml. Both populations were predominantly serotype cross-reactive. This sharp specificity divergence suggests different MBC subsets feed the PB vs. convalescent MBC compartments (see Appanna2016 - Plasmablasts as Subset of Memory B Cell Pool, mAb cloning + ELISA + neutralisation, n=7 patients for PBs, n=4 for MBCs).

  • VH4-34 and VH1-69 (autoantigen-binding VH genes) enriched in plasmablasts: Some VH gene families with self-antigen-binding potential were observed specifically among PB-derived DENV-specific Abs but not MBC-derived Abs, suggesting the acute PB wave may include autoreactive/polyreactive antibodies (see Appanna2016 - Plasmablasts as Subset of Memory B Cell Pool, single-cell VH sequencing).

  • Comparable VH mutation frequencies between PBs and MBCs despite clonal unrelatedness: Despite being clonally distinct, plasmablast-derived and MBC-derived antibodies showed similar VH nucleotide mutation rates and N-addition counts (not significantly different by ANOVA). This argues against a model where MBCs undergo substantially more GC maturation than PBs and suggests both derive from similarly matured precursors with different specificities (see Appanna2016 - Plasmablasts as Subset of Memory B Cell Pool, IMGT analysis, n=12 patients).

  • HIGH SHM IN SORTED SECONDARY DENGUE PLASMABLASTS — strongest evidence for memory origin: Single-cell VH sequencing of sorted plasmablasts from 4 secondary DHF patients (DENV2) revealed high SHM: per-patient averages of 14.5–21.7 VH mutations (overall mean 18.1, range 5–39), significantly higher than IgG⁺ GC B cells (p<0.005) and comparable to influenza recall responses. CDR R:S ratios >2.9 confirmed antigenic selection. 23% of plasmablast VH sequences were clonally related (range 15–28%), further supporting recall of pre-existing memory clones. 53 mAbs were generated: 70% E-specific (all cross-reactive to ≥2 serotypes), 46/53 neutralising, 45/53 ADE-competent. Evidence of Original Antigenic Sin in 2/4 patients — DENV1-biased neutralisation despite DENV2 infection, with DENV1-specific mAbs more potent (FRNT₅₀ 0.16 µg/ml) than DENV2-specific (1.2 µg/ml). Nearly universal Antibody-Dependent Enhancement regardless of neutralisation potency (see Priyamvada2016 - Cross-Reactive Memory Plasmablasts in Secondary Dengue, n=4 secondary DHF, single-cell mAb cloning, 53 mAbs).

  • Plasmablast analysis alone is an insufficient correlate of long-term DENV immunity: Because the PB wave represents only a narrow, E-specific IgG⁺ subset of the broader DENV-specific memory B cell pool (Appanna2016), measuring plasmablast magnitude or specificity does not capture MBC diversity, bone marrow-resident long-lived plasma cells, or potentially tissue-retained PBs. The isotype-fate segregation model (IgG⁺ MBCs → PBs, IgM⁺ MBCs → GC re-entry; Seifert et al. 2015) provides a mechanistic explanation for this selective recruitment (see Bhattacharya2016 - Memory B Cell Subset Selection in Secondary Dengue, commentary — no original data).

  • Alternative lineage atBCs do NOT upregulate PC maintenance genes — challenges the pre-plasmablast model: scRNA-seq of >12,000 B cells showed that no alternative lineage cluster (atBC1, atBC2, atBC3, MBC1) upregulated XBP1, IRF4, or PRDM1 (BLIMP-1). PCs were detached from the pseudotime manifold with no intermediate population bridging atBCs to PCs. This argues against atBCs/DN2 cells being obligate pre-plasmablasts in healthy or infection contexts. However, Sutton’s own Discussion notes that in SLE, chronic TLR7 stimulation can drive atBCs to PC fate — the pre-plasmablast identity is context-dependent, not a fixed property (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, n=4, 10x Chromium + pseudotime).

  • Dengue acute-phase plasmablasts carry paradoxically low SHM — lower in severe and secondary disease: HTS of IgG VH cDNA (enriching for ASCs by RNA abundance) revealed that acute-phase IgG B cells have globally lower SHM than post-convalescent IgG B cells (p<0.001), with SHM further reduced in DWS+ vs. DWS− and in secondary vs. primary infections. Monte Carlo simulation confirmed the acute signal derives predominantly from plasmablasts (probability of sampling mB cell = 0.015). Convergent CDRH3 signatures shared across up to 52% of patients were found specifically among the most hypomutated clones. The low SHM in plasmablasts with class-switched (IgG) status indicates CSR without extensive SHM — consistent with GC-independent (extrafollicular) differentiation (see GodoyLozano2016 - Lower IgG SHM Rates in Acute Dengue, n=19 acute dengue, 454 pyrosequencing, 385,206 lineages).

  • ★ Early plasma cells (ePCs) are one of three fates of a tripotent pre-GC precursor — and higher affinity favours them. Activated precursors at the T–B border can become early plasma cells, early memory B cells, or GC B cells; limiting-dilution transfer shows a single naive B cell can seed all three, with the split evident by day 4 post-immunization. Higher-affinity BCRs and stronger T-derived signals favour ePC generation, while lower-affinity antigen more often yields early MBCs; supplying additional antigen several days into the response pushes early activated B cells toward the ePC lineage (see Glaros2025 - Multilayered Identity of B Cell Memory, review, no original data, mouse). Note this is the opposite directionality from the SLE EF model, where DN2→PC proceeds on innate signals without BCR stimulation (Jenks2018 - DN2 B Cells and EF Pathway in SLE) — see Extrafollicular Response Contradictions.

  • Memory-derived PCs, not primary-infection long-lived PCs, carry cross-variant protection. The review states that protective antibodies against flavivirus and influenza variants arise primarily from rapid differentiation of memory B cells into PCs rather than from long-lived plasma cells established during primary infection, and attributes this to the greater clonal diversity of the memory compartment (see Glaros2025 - Multilayered Identity of B Cell Memory, review). Directly relevant to dengue serotype cross-protection and to the wiki’s plasmablast–neutralization disconnect.

  • Cumulative stimulation epigenetically biases memory toward PC output. Repeated antigenic stimulation progressively opens PC-associated loci including Prdm1, raising baseline BLIMP-1 and biasing MBCs toward PC differentiation over GC reentry, via BACH2/BLIMP1 (see Glaros2025 - Multilayered Identity of B Cell Memory, review; untested). See Memory B Cell; for the wiki-generated dengue application see Original Antigenic Sin.

  • Tissue-resident memory can produce PCs on innate signals alone. Some lung resident memory B cells recruited to an infection site — including cells with no specificity for the invading pathogen — differentiate into PCs in response to innate signals without cognate antigen, a speed-over-precision trade-off in vital tissue (see Glaros2025 - Multilayered Identity of B Cell Memory, review, mouse). See Tissue-Resident Memory B Cell.

  • ★ T-bet represses Blimp-1 — ABC→plasma cell differentiation likely requires losing T-bet, but the claim is unreferenced. ABCs differentiate rapidly to antibody-secreting cells on TLR7/9 stimulation plus IL-21 (citing Wang et al. 2018 and this wiki’s own Jenks2018 - DN2 B Cells and EF Pathway in SLE). Cancro adds: “few if any plasma cells express T-bet, and there is evidence that T-bet represses Blimp-1, suggesting that the formation of plasma cells from ABCs likely involves the loss of T-bet expression.” ⚠ This sentence carries no numbered citation in the review — flag as an unreferenced assertion pending independent verification, not an established mechanism (see Cancro2020 - Age-Associated B Cells, review — no original data; mouse and human, unreferenced assertion within the review).

  • The ABC-as-plasma-cell-depot hypothesis. The splenic ABC memory pool may be a continuously replenishing source of PC precursors, potentially explaining how the bone marrow niche sustains lifelong plasma cell production without continuous enlargement or loss of prior specificities — consistent with Allman-group data showing a significant fraction of bone marrow plasma cells turn over rapidly. Cancro flags this as explicitly requiring fate-mapping tools to test (see Cancro2020 - Age-Associated B Cells, review — no original data; mouse).

  • IgM⁺CD11c⁺ extrafollicular splenic plasmablasts drive CD4-T-independent antibody responses in murine Ehrlichia infection (Racine et al. 2008, J Immunol), alongside protective, multipotential T-bet⁺ memory B cells generated in the same GC-absent response (see Cancro2020 - Age-Associated B Cells, review — no original data; mouse).

  • ⚠ Finding an ASC at an extrafollicular site is not evidence of an extrafollicular response. The consensus Perspective flags this as a specific trap: the final maturation of GC-derived plasma cells happens outside the follicle — precursors move to the splenic bridging channels and red pulp, or to the LN medulla — and GC-derived plasmablasts can still undergo T cell-based selection in the LN medulla after exiting the GC. Verbatim: “Although these areas overlap with EF locations, these ASCs are GC-derived and should not be confused with EF response-derived ASCs.” The corollary for blood-based work is stronger still: a circulating plasmablast carries no location information at all (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • Plasmablast vs. plasma cell, as the consensus glossary defines them. PBs are proliferating ASCs found in secondary lymphoid tissues, able to migrate to tissues but thought to be transient (Ki67⁺, CD19⁺CD20^lo CD27⁺CD38⁺CD138^+/− HLA-DR⁺CXCR5⁻ in humans). PCs are terminally differentiated and non-proliferating, short- or long-lived, residing in bone marrow, spleen, thymus and mucosal sites (Ki67⁻, CD19^lo CD20⁻ CD27⁺CD38⁺CD138⁺CXCR5⁻). Cell-cycle status, not surface phenotype alone, is the dividing line — which makes Ki67 the discriminating marker rather than a supplementary one (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • Both pathways generate plasmablasts; they differ in kinetics and relative contribution, not in cell type produced. GC-independent responses rapidly generate short-lived PBs — some in LN medullary cords — giving the first wave of antigen-induced antibody, and also generate long-lived PCs and early memory B cells. GC responses produce short- and long-lived PCs and memory later. The relative contribution of each to the bone marrow, splenic, and mucosal PC pools “is still being defined” (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • ★ [2026-08-27] Plasmablast frequency correlates with DN3 frequency more strongly than with any other DN subset. In IgG4-related disease blood (n=38, Spearman): DN3 r = 0.6566, p < 0.0001; DN2 r = 0.4496, p = 0.0067; DN4 r = 0.4037 (ns); DN1 r = −0.1420 (ns). Sorted DN3 also carried a transcriptome with proliferation, unfolded-protein-response and antibody-secreting-cell features plus high IGHG4 message (n=4). Together these are the wiki’s principal quantitative support for a DN3→plasmablast relationship — but both are associative: no pseudotime, clonal-connectivity or transfer evidence is presented (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=38 + n=4).

  • [2026-08-27] Plasmablasts discriminate IgG4-RD from health, but so do the DN subsets. Logistic regression: plasmablasts OR 2.839 (95% CI 1.214–6.643), p = 0.0161; DN total OR 1.591 (1.14–2.219); DN2 OR 5.381 (1.58–18.32); DN3 OR 113.5 (4.509–2857.1); DN4 OR 18.7 (1.745–200.97). ⚠ The paper reads the DN ORs as “higher than plasmablasts,” but odds ratios scale with predictor units and these subsets span very different frequency ranges, so cross-predictor magnitude comparison is not valid without standardisation; the DN3 interval spans a 634-fold range (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=38).

  • [2026-08-27] In inflamed tissue, plasmablasts form T-B conjugates with CD4⁺ T cells — but are outnumbered by DN cells. In IgG4-RD salivary gland (n=4), CD19⁺IgD⁻CD27⁺CD20⁻ plasmablasts were less abundant than DN B cells, and conjugates with T cells occurred primarily between DN cells and T cells and between plasmablasts and T cells, rarely with switched memory cells. Plasmablasts expressed the highest CD86 of any B cell subset examined (n=13) (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=4 tissue IF). See Extrafollicular T Cell Help.

  • ⚠ [2026-08-27] Do plasmablasts express more or less HLA class II than DN3? The primary contradicts itself — quarantined. The Results text says plasmablasts expressed lower HLA class II than DN3; the Fig. S3 legend says DN3 downregulates HLA class II. The direction cannot be resolved from the published article and no synthesised HLA-II claim is carried here (per the [2026-08-23] inconsistent-reporting rule; full record on the source page) (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=13).

  • The core-marker ASC gate, and the five-way subdivision beneath it. All circulating ASC can be identified with core markers as CD19⁺IgD⁻CD38⁺⁺; they also express high CD27 and downregulate CD20. Subgating IgD⁻ cells on CD138 vs CD38 then resolves five fractions (Pop1 CD19⁺CD38ᵐⁱᵈCD138⁻ → Pop5 CD19⁻CD38ʰⁱCD138⁺). Separately, core markers reveal circulating pre-plasmablasts: proliferative IgD⁻CD38⁺/⁺⁺CD24⁻ cells expressing low CD27, which upregulate BLIMP-1 while retaining Pax5. Circulating ASC are largely Ki-67⁺ whereas bone-marrow ASC show little Ki-67 — a newly-generated versus resident distinction (see Sanz2019 - Consistent Classification of Human B Cell Populations, review — no original data).

  • [2026-08-29] Plasmablast expansion is shared across the whole lupus spectrum, including skin-limited disease. PB were gated IgD⁻CD27⁺⁺CD38⁺⁺ and were expanded in primary cutaneous lupus as well as in both SLE groups, alongside unswitched-memory contraction and DN expansion — at lower magnitude in the skin-limited group. PB clustered with activated naive, DN2 and DN3 as a single effector family in unsupervised analysis (see Jenks2021 - B Cell Subset Composition in Cutaneous Lupus, n=207 patients + 46 healthy controls, cross-sectional, conventional flow). Methodological note: switched memory frequency was derived by subtracting the PB frequency from the IgD⁻CD27⁺ compartment, so PB gate placement propagates directly into the switched-memory number on this panel.

  • ★ T-bet expression across ASC compartments is an anatomical gradient — a caution for reading blood plasmablasts. Using a Tbx21-ZsGreen reporter 60 days after influenza, splenic ASCs were 32.5 ± 19.4% reporter⁺ (vs 9.6 ± 2.5% of splenic B cells) whereas bone-marrow long-lived ASCs were only 0.87 ± 0.8% (vs 1.11 ± 0.7%) (see Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation, mouse, reporter flow cytometry). T-bet reporter⁺ cells also included GC B cells and memory B cells. A plasmablast’s T-bet status therefore does not by itself identify its compartment of origin or its pathway — relevant to any blood-only cohort design. This refines, rather than supports, Cancro’s “few if any plasma cells express T-bet” (see T-bet).

  • Mouse ASC gating in this system is CD138⁺CD93⁺, not CD138 alone. Day-4 Be1 cultures were subdivided by CD138 and CD93 into four populations; the CD138⁺CD93⁺ double-positive subset produced the most antibody by secretory rate and by ELISPOT per equivalent cell number, and CD93 single-positive cells did not. Reporting a CD138⁺-only frequency would over-call the secreting population (see Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation, mouse, in vitro, sort-purified). Compare the human CD27⁺⁺CD38⁺⁺ convention used elsewhere in the wiki — the marker sets are not interchangeable.

  • ★ An extrinsic, myeloid driver of plasmablast differentiation, established by blockade. DENV-2-infected CD14⁺ monocytes (MOI 1, 48 h — which converts >70% of them to a CD14⁺CD16⁺ phenotype) cocultured for 6 days with allogeneic resting CD19⁺ B cells plus IL-2 and CpG drove CD27⁺⁺CD38⁺⁺ plasmablasts to 22.8% of total B cells, versus 5.21% with monocyte-derived DCs and 3.83% with B cells alone, predominantly within the CFSE-diluted proliferating fraction. Blocking arms: anti-BAFF and TACI-Fc “modestly diminished” differentiation, anti-IL-10 “significantly blocked” it, and anti-IL-6 and anti-IP-10 did not — the authors attribute the effect to BAFF/APRIL plus IL-10 (see Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue, in vitro, 4 independent experiments with 4 healthy blood donors). No T cells were present in the culture. This is the wiki’s myeloid counterpart to the Tph/IL-21 arm of Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue; the two have never been weighed against each other in the same patient. Effect sizes for the blockade arms are in supplementary Figure S5, which is not in the wiki’s PDF — only the authors’ qualitative wording is quoted here.

  • In the patient cohort, plasmablast numbers track late, low-viraemia illness — not severity. Increased plasmablast numbers correlated with duration of illness, and XBP-1 target genes (the unfolded protein response driving plasma-cell differentiation) were significantly enriched in the low-VL group, i.e. late in disease; B cell gene signatures likewise correlated negatively with viral load. Meanwhile CD14⁺CD16⁺ monocyte numbers did not correlate with antibody titres, which the authors ascribe to the differing kinetics of the two cell types rather than to absence of a relationship (see Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue, n=28 acute secondary dengue, single sample per patient at days 2–9 of symptoms). The single-timepoint design means all kinetics here are inferred cross-sectionally.

  • The ASC endpoint of the EF pathway is T-bet^lo^IRF4^hi^ — T-bet falls as the cell finishes differentiating. The pathway runs B_N_ →(anti-Ig, R848, IFN-γ)→ pre-ASC (T-bet^hi^IRF4^int^) →(R848, IL-21)→ ASC (T-bet^lo^IRF4^hi^), with ASCs gated as CD38^hi^CD27⁺ (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human, n=20 HD + n=40 SLE + in vitro reconstruction). Two constraints on ASC yield are worth carrying: IL-21 is obligate (no ASCs without it) and BCR stimulation must be transient — continuous anti-Ig gave 2.8% ASCs versus 49% with anti-Ig restricted to days 0–3. The T-bet^hi^→T-bet^lo^ transition is consistent with the compartment gradient reported in Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation and gives a mechanism for it.

  • ★ An intermediate secretory state: these cells secrete antibody without a TLR stimulus, but need one to secrete autoantibody. By ELISpot the sorted murine T-bet⁺CD11c⁺ population already contained anti-LCMV IgG-secreting cells before R848, increasing after — placing it between IgD^lo^CD38⁺GL-7⁻ memory B cells, which were reliant on TLR stimulation, and plasma cells (CD19^int^CD138⁺), which were independent of it. Yet on anti-dsDNA and anti-chromatin ELISpot the same cells rarely secreted autoantibody in the absence of R848, despite containing a higher frequency of autoreactive producers, so further differentiation toward ASC is required before they contribute to serum autoreactivity (see Song2022 - Tfh Outside Germinal Centers Drive T-bet CD11c B Cells, mouse, LCMV-Armstrong, n=3–5 mice/group). Directly relevant to reading a circulating atypical/DN2 frequency as a proxy for antibody output.

Contradictions & Debates

  • SHM discrepancy in dengue plasmablasts: high (Priyamvada2016) vs. low (GodoyLozano2016). Priyamvada2016 finds high SHM (mean 18.1 VH mutations ≈ ~6.5% nucleotide mutation) in sorted plasmablasts from secondary DHF, while GodoyLozano2016 finds globally low SHM in bulk IgG VH cDNA from a mix of primary and secondary infections. Likely reconciliation: Priyamvada2016 sorted plasmablasts specifically from secondary DHF (all memory-derived), while GodoyLozano2016 captured the full IgG⁺ B cell pool (including de novo EF-derived low-SHM PBs that dilute the average). Both studies may be correct — secondary infections contain a mixture of memory-derived high-SHM PBs and de novo low-SHM PBs, with the ratio depending on infection history and methodology.
  • The relative contributions of short-lived plasmablasts vs. long-lived plasma cells to serum antibody levels in SLE (and by extension in dengue) remains unresolved. The same patient can harbour both populations, and their relative proportions may differ by disease stage, treatment status, and anatomical compartment.
  • Whether the rapid decline in circulating plasmablasts after rituximab reflects true cell death or redistribution (homing to bone marrow or inflamed tissue) cannot be fully excluded, though serum autoantibody normalization in some patients supports actual cell death.

DN2 B Cell, Double-Negative B Cell, Activated Naive B Cell, Memory B Cell, CD38, CD138, CD20, CD27, CD19, IRF4, BLIMP-1, TLR7, Extrafollicular Response, Bm Classification, Germinal Center, Original Antigenic Sin, Antibody-Dependent Enhancement, Early Memory B Cell, Tissue-Resident Memory B Cell, BACH2, GC-Independent Response, DN3 B Cell

Sources

Graph View

Backlinks